CORE-003: BIOSPECIMEN SERVICES SHARED RESOURCE (BSSR) PROJECT SUMMARY / ABSTRACT The OSUCCC Biospecimen Services Shared Resource (BSSR) is a longstanding SR whose broad mission is to provide high quality biospecimen procurement, processing, storage and distribution to OSUCCC researchers. The BSSR is directed by Ms. Heather Hampel, who also is the OSUCCC Associate Director for Biospecimen Science. The BSSR is comprised of two arms: the first arm is for collection using a universal consenting and biobanking protocol that has been substantially modified and that was IRB-approved one year ago. It is modeled and named after the existing Total Cancer Care (TCC) protocol in place at Moffitt Cancer Center. The TCC protocol includes a broad informed consent allowing for access to pathologic and clinical data for life, with the ability to re-contact patients for clinical follow up and/or to offer participation in other clinical trials for which they are eligible. The collected tissues are stored at the BSSR biobank, located at OSU's Nationwide Children's Hospital Biopathology Center, which is both NCI funded and approved by the College of American Pathologists. During the first 11 months of the TCC protocol consenting process, 6,494 cancer patients have been consented, representing a 90% accrual rate for contacted subjects. There are 24,346 aliquots collected, and 2,050 paraffin-embedded tissues are available. The second arm of the BSSR provides prospectively procured biospecimens to OSUCCC investigators from all five OSUCCC research programs who are in need of pathology samples. The decision to distribute BSSR tissues is decided by committee who evaluates scientific merit, source of funding and availability. Researchers may receive samples and data with subject identifiers with prior IRB-approval, or de-identified and coded- limited data sets without additional prior IRB approvals. Over the past five-year period, the BSSR has provided 56 OSUCCC investigators with 17,617 prospectively-procured samples from 4317 subjects among 73 IRB protocols, and has contributed to 88 publications, including 8 in journals with an impact factor >10. Also, the BSSR provided services for prospective procurement to 2 SPORES, 10 R01s, 4 R21s, 3 U01s, 3 P01s, 2 K awards, and a T32. Future plans for BSSR are to complete the implementation of the TCC protocol in all of the OSUCCC's Disease Specific Research Groups, to reduce the number of IRB-approved banking protocols across the OSUCCC, to establish web-based consenting and electronic patient questionnaires, and to develop collaborative relationships with other NCI-designated CCC's for data sharing and enhancement of research. The BSSR leverages extensive institutional support and seeks only 9.3% support from CCSG funds. Biospecimen Services Shared Resource is part of the Clinical Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-42
Application #
9390841
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications